✦ LIBER ✦

Carbohydrate vaccines that induce antibodies against cancer. 1. Rationale

✍ Scribed by Philip O. Livingston; Shengle Zhang; Kenneth O. Lloyd

Book ID: 105968222
Publisher: Springer-Verlag
Year: 1997
Tongue: English
Weight: 964 KB
Volume: 45
Category: Article
ISSN: 0340-7004
DOI: 10.1007/s002620050394

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Recombinant multi-epitope vaccine induce

Recombinant multi-epitope vaccine induce predefined epitope-specific antibodies against HIV-1

✍ Hua Li; Zu-Qiang Liu; Jian Ding; Ying-Hua Chen 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 184 KB

Candidate multi-epitope vaccines in alum

Candidate multi-epitope vaccines in aluminium adjuvant induce high levels of antibodies with predefined multi-epitope specificity against HIV-1

✍ Jian Ding; Yun Lu; Ying-Hua Chen 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 297 KB

Vaccine induced HSV 1 antibodies fail to

Vaccine induced HSV 1 antibodies fail to correlate with protection against HSV 2 in guinea pigs

✍ M.J. Welch; P.H. Ridgeway; R.J. Phillpotts 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 376 KB

Antibody-dependent cell-mediated cytotox

Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients

✍ Frank G.M. Snijdewint; Silvia von Mensdorff-Pouilly; Augustine H. Karuntu-Wanama 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 161 KB

Human polymorphic epithelial mucin (PEM, MUC1) is a high molecular weight transmembrane glycoprotein expressed on the apical cell surface of glandular epithelium and is over-expressed and hypo-glycosylated in adenocarcinomas. The extracellular part of the molecule consists mainly of a variable numbe

Epitope specificity of murine and human

Epitope specificity of murine and human bactericidal antibodies against PorA P1.7,16 induced with experimental meningococcal group B vaccines

✍ Eileene M. Rouppe van der Voort; Betsy Kuipers; Humphrey F. Brugghe; Leontine M. 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 647 KB

Phase II trial of mapatumumab, a fully h

Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

✍ Trarbach, T; Moehler, M; Heinemann, V; Köhne, C-H; Przyborek, M; Schulz, C; Snel 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 318 KB